Illumina unveiled TruPath Genome at AGBT, pairing proximity mapped read technology with DRAGEN Germline to improve mapping in “dark” genomic regions and boost structural variant detection and ultralong phasing. At UMC Utrecht, early evaluation in rare-disease samples reported megabase-scale phasing, full resolution of clinically relevant genes, and improved interpretation of hard-to-analyse loci including SMN1/SMN2.

Why It Matters To Oncology

• Better mapping in difficult regions can reduce blind spots that complicate structural variant calling—relevant for tumor suppressor loci, complex rearrangements, and challenging paralogous regions.

• Illumina also highlighted multiomic cancer workflows (spatial transcriptomics + 5-base sequencing + proteomics) aimed at reading tumor biology in context rather than as siloed datasets.

• In studies presented, integrated spatial/genomic/proteomic review helped identify a novel set of cancer-associated fibroblasts and distinguish malignant from benign samples.

• Broad Clinical Labs and partners combined whole-genome + methylation profiling in pediatric renal cancers, using methylation-based classifiers to identify rhabdoid tumors that genomics-only approaches missed.

The Financials

• Illumina did not disclose pricing or reimbursement details for TruPath Genome in the information shared from AGBT.

• Near-term economic impact for oncology labs will likely depend on whether TruPath can replace orthogonal confirmation for complex variants and how it fits into existing short-read workflows.

• Multiomic stacks (spatial + methylation + proteomics) may increase per-sample cost, but could improve yield in discovery programs by reducing iterative testing.

What They're Saying

• Illumina: TruPath “combines the proven accuracy of short-read sequencing with long-distance genomic insights” to improve mapping, enhance structural variant detection, and deliver ultralong phasing.

• Marcel Nelen (UMC Utrecht): “an important step toward a single assay capable of addressing many rare disease research questions without additional orthogonal testing.”

• Cande Rogert (Illumina): High-resolution spatial profiling enabled analysis of tumor genetics “within their real context” and identification of new cell subtypes.

What's Next

• Watch for oncology-specific validation: sensitivity/precision for clinically relevant structural variants (including low-VAF contexts), performance in FFPE, and comparability vs long-read and optical mapping.

• Expect more evidence on how proximity mapping changes interpretation in notoriously difficult regions and whether it reduces confirmatory testing.

• Broad and collaborators are expanding methylation + genome profiling to additional FFPE and cell-free DNA samples—key for translational and minimal residual disease-adjacent discovery work.

• If multiomic integration continues to separate malignant from benign and surface new stromal subtypes (e.g., cancer-associated fibroblasts), it could accelerate target discovery and biomarker stratification.